![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana (T.P.B., C.M., K.A.H., H.E.O., W.P.B., B.C.Y., C.C.C., R.W.Z., R.J.B., C.D.H., V.K., H.A.B., L.L.B., R.J.G., K.B., K.R.S.); and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana (T.P.B., K.B.)
Abstract
Guggulsterone (GS) is the active substance in guggulipid, an extract of the guggul tree, Commiphora mukul, used to treat a variety of disorders in humans, including dyslipidemia, obesity, and inflammation. The activity of GS has been suggested to be mediated by antagonism of the receptor for bile acids, the farnesoid X receptor (FXR). Here, we demonstrate that both stereoisomers of the plant sterol, (E)- and (Z)-GS, bind to the steroid receptors at a much higher affinity than to FXR. Both stereoisomers bind to the mineralocorticoid receptor (MR) with a Ki value of approximately 35 nM, which is greater than 100 times more potent than their affinity for FXR. Both (E)- and (Z)-GS also displayed high affinity for other steroid receptors, including the androgen (AR), glucocorticoid (GR), and progesterone receptors (PR) with Ki values ranging from 224 to 315 nM. In cell-based functional cotransfection assays, GSs behaved as antagonists of AR, GR, and MR, but as agonists of PR. Agonist activity was also demonstrated with estrogen receptor (ER) 
; however, the potency was very low (EC50 > 5000 nM). In addition, GS displayed activity in functional assays in cell lines expressing endogenous AR, GR, ER, and PR. These data suggest that the variety of pharmacological effects exhibited by GS may be mediated by targeting several steroid receptors.
Received for publication September 9, 2004.
Accepted for publication December 14, 2004.
Address correspondence to: Dr. Thomas P. Burris, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: burris{at}lilly.com
This article has been cited by other articles:
|
|
 |
|
  P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation Physiol Rev, January 1, 2009; 89(1): 147 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Deng, D. Yang, A. Radke, J. Yang, and B. Yan The Hypolipidemic Agent Guggulsterone Regulates the Expression of Human Bile Salt Export Pump: Dominance of Transactivation over Farsenoid X Receptor-Mediated Antagonism J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1153 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rizzo, M. Disante, A. Mencarelli, B. Renga, A. Gioiello, R. Pellicciari, and S. Fiorucci The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo Mol. Pharmacol., October 1, 2006; 70(4): 1164 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Hanniman, G. Lambert, T. C. McCarthy, and C. J. Sinal Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice J. Lipid Res., December 1, 2005; 46(12): 2595 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Samudio, M. Konopleva, S. Safe, T. McQueen, and M. Andreeff Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure Mol. Cancer Ther., December 1, 2005; 4(12): 1982 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ding and J. L. Staudinger The Ratio of Constitutive Androstane Receptor to Pregnane X Receptor Determines the Activity of Guggulsterone against the Cyp2b10 Promoter J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 120 - 127. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
